BridgeMD
New treatment option for Head and Neck Neoplasms
Official title Foot Reflexology and Ta-VNS for Symptom Management in Head and Neck Cancer During CCRT
ClinicalTrials.gov ID: NCT07711626
What this study is testing
- What it's testing
- Head and neck cancer (HNC) patients undergoing concurrent chemoradiotherapy (CCRT) frequently experience pain, xerostomia, fatigue, sleep disturbance, and other treatment-related toxicities that impair quality of life and treatment adherence, with incomplete relief from current supportive care. This randomized, single-blind, sham-controlled trial evaluates whether foot reflexology (FR), transcutaneous auricular vagus nerve stimulation (ta-VNS), and auricular acupressure (AA) reduce pain, xerostomia, fatigue, sleep disturbance, and treatment-related symptoms in HNC patients receiving cisplatin-based CCRT, compared with usual care.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 30 to 75
You may be able to join if
- Pathologically confirmed head and neck cancer, clinical stage II-IVA, age 30-75 years, conscious, able to communicate and comprehend, and able to...
- Scheduled to receive a second cycle of cisplatin-based concurrent chemoradiotherapy
- ECOG performance status ≤2
You likely can't join if
- Severe cognitive impairment or psychiatric illness precluding comprehension or cooperation
- Open wounds or skin lesions of the foot or ear, lower-limb edema, history of deep vein thrombosis, or diabetes with most recent HbA1c \>7.5%
- Cardiac pacemaker or other implanted electronic device, or other severe cardiovascular disease
- Severe bone-marrow suppression (WBC \<2,000/µL or platelets \<50,000/µL)
- Pregnant or breastfeeding women
- History of epilepsy or seizures
See the full eligibility criteria
- Pathologically confirmed head and neck cancer, clinical stage II-IVA, age 30-75 years, conscious, able to communicate and comprehend, and able to comply with study procedures
- Scheduled to receive a second cycle of cisplatin-based concurrent chemoradiotherapy
- ECOG performance status ≤2
- Severe cognitive impairment or psychiatric illness precluding comprehension or cooperation
- Open wounds or skin lesions of the foot or ear, lower-limb edema, history of deep vein thrombosis, or diabetes with most recent HbA1c \>7.5%
- Cardiac pacemaker or other implanted electronic device, or other severe cardiovascular disease
- Severe bone-marrow suppression (WBC \<2,000/µL or platelets \<50,000/µL)
- Pregnant or breastfeeding women
- History of epilepsy or seizures
- Physically frail condition
The study team makes the final eligibility decision.
Where it's taking place
- Hualien City, Taiwan
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 30 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Hualien City, Taiwan. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.